Plasminogen Activator Inhibitor 1 Activity and Other Coronary Risk Factors

Abstract

Because only some coronary risk factors have been evaluated for an association with plasma plasminogen activator inhibitor 1 (PAI-1) activity, this cross-sectional study examined the association between 27 coronary risk factors and PAI-1 in 24 healthy persons without coronary heart disease (control persons) and 22 patients who had survived myocardial infarction (cases). The coronary risk factors included major coronary risk factors such as age, anthropometric measures such as intraabdominal fat, and biochemical analytes such as serum concentration of triglyceride and plasma von Willebrand factor activity. The associations were analyzed in univariate and multiple linear regression analyses. For the control persons, triglyceride and von Willebrand factor were significantly associated with PAI-1 activity (p=0.0002, R²=0.55). In contrast for the 24 cases, age and intraabdominal adipose tissue were significantly associated with PAI-1 (p=0.0011, R²=0.51). Coronary risk factors explained more than half the variation of PAI-1 activity for both study groups. However, healthy persons and patients with previous myocardial infarction differed regarding coronary risk factors associated with PAI-1.

Keywords

Plasminogen activator inhibitor Triglyceride von Willebrand factor Age Obesity

References

Thogersen AM , Jansson JH , Boman K , et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241.

Juhan-Vague I , Pyke SD , Alessi MC , et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996;94:2057.

Leander K , Wiman B , Hallqvist J , et al. PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction. Results from the Stockholm Heart Epidemiology Program (SHEEP). Thromb Haemost 2003;89:1064.

Eliasson M , Evrin PE , Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure: The North Sweden MONICA Study. J Clin Epidemiol 1994;47:513.

Shimomura I , Funahashi T , Takahashi M , et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 1996;7:800.

Sasaki A , Kurisu A , Ohno M , Ikeda Y. Overweight/obesity, smoking, and heavy alcohol consumption are important determinants of plasma PAI-1 levels in healthy men. Am J Med Sci 2001;322:19.

von Eyben FE , Mouritsen E , Holm J , et al. Intra-abdominal obesity and metabolic risk factors: A study of young adults. Int J Obes Metab Rel Disord 2003;27:941.

von Eyben FE , Mouridsen E , Holm J , et al. Smoking, low density lipoprotein cholesterol, fibrinogen and acute myocardial infarction before 41 years of age: A Danish case-control study. J Cardiovasc Risk 2002;9:171.

Stief TW , Lenz P , Becker U , Heimburger N. Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in the presence of oxidants: a novel principle. Thromb Res 1988;50:559.

10.

Svalastoga K. Prestige, Class, and Mobility. Copenhagen: Munksgaard, 1959.

11.

Hansen EJ . Social Groups in Denmark (Socialgrupper i Danmark). Copenhagen: The Institute of Social Sciences,1984.

12.

Alberti KG , Zimmet PZ . Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998;15:539.

13.

Altman DG . Practical Statistics for Medical Research. London: Chapman and Hall, 1991.

14.

von Eyben F , von Eyben R. Smoking and other major coronary risk factors and acute myocardial infarction before 41 years of age: Two Danish case-control studies. Scand Cardiovasc J 2001;35:25.

15.

Juhan Vague I , Thompson SG , Jespersen J. Involvement of the hemostatic system in insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993;134:865.

16.

Vague P , Juhan Vague J , Chabert V , et al. Fat distribution and plasminogen activator inhibitor activity in non-diabetic obese women. Metabolism 1989;38:913.

17.

Mehta J , Mehta P , Lawson D , Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary atery disease: Correlations with age and serum triglyceride concentrations. J Am Coll Cardiol 1987;98:263.

18.

Sundell B , Nilsson TK , Hallmans G , et al. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population. Atherosclerosis 1989;80:9.

19.

Landin K , Tengborn L , Smith U. Elevated fibrinogen and plasminogen activator inhibitor in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273.

20.

Chadarevian R , Bruckert E , Dejager S , et al. Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: Lack of a threshold value. Thromb Res 1999;96:175.

21.

Nilsson TK , Boman K , Bjerle P , et al. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med 1994;235:419.

22.

Eliasson M , Asplund K , Evrin PE , Lundblad D. Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. Metabolism 1994;43:1579.

23.

Pannacculi N , De Mitrio V , Marino R , et al. Effects of glucose tolerance on PAI-1 plasma levels in overweight and obese subjects. Obese Res 2002;10:717.

24.

He G , Bruun JM , Lihn AS , Pedersen SB , Richelsen B. Stimulation of PAI-1 and adipokines by glucose in human adipose tissue in vitro. Biochem Biophys Res Commun 2003;310:878.